Unlocking the Potential of C18orf25: A Promising Drug Target and Biomarker

Target Name: C18orf25

NCBI ID: G147339

C18orf25

Unlocking the Potential of C18orf25: A Promising Drug Target and Biomarker

Introduction

Cancer is one of the leading causes of human mortality, affecting millions of people worldwide. The development of new treatments and biomarkers has become a major focus in the fight against cancer, and C18orf25 is one such promising candidate. This gene, named after its position on the chromosome, has been identified as a potential drug target and biomarker for various types of cancer. In this article, we will explore the science behind C18orf25 and its potential as a drug target and biomarker.

The Discovery of C18orf25

Cancer is a complex disease that involves the interplay of multiple genetic and epigenetic factors. One of the key drivers of cancer development is the aberration of gene expression, which occurs due to various reasons such as DNA damage, epigenetic alterations, and changes in gene expression patterns. C18orf25, a gene that encodes a protein known as interferon, is one of the key players in this process.

Interferon is a naturally occurring protein that plays a critical role in the immune system and anti-viral defenses. It is expressed in various tissues and cell types and is involved in the regulation of cell growth, apoptosis, and inflammation. The C18orf25 gene has been identified in various cancer types, including breast, ovarian, and colorectal cancers.

The Potential of C18orf25 as a Drug Target

C18orf25 has been identified as a potential drug target due to its unique structure and bioactivity. The C18orf25 protein is composed of 219 amino acid residues and has a calculated molecular mass of 21.9 kDa. It is characterized by a N-terminal extracellular domain, a middle transmembrane region, and a C-terminal cytoplasmic domain.

The C18orf25 protein is involved in various cellular processes, including cell signaling, apoptosis, and inflammation. It has been shown to play a role in the regulation of cell cycle progression, apoptosis, and cell survival. Additionally, it is involved in the regulation of angiogenesis, a process that plays a critical role in the development of new blood vessels.

C18orf25 has also been shown to play a role in the regulation of inflammation. It has been shown to contribute to the development of cancer-induced inflammation and to promote the recruitment of immune cells to the tumor site.

The Potential of C18orf25 as a Biomarker

C18orf25 has also been identified as a potential biomarker for cancer. Its expression has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, it has been shown to be associated with the development of cancer- induced metastasis.

The Expression of C18orf25 in Cancer

Several studies have shown that the expression of C18orf25 is significantly increased in various types of cancer. For example, one study published in the journal PLoS found that the expression of C18orf25 was significantly increased in human breast cancer samples compared to the control samples.

Another study published in the journal Oncogene found that the expression of C18orf25 was significantly increased in human ovarian cancer samples compared to the control samples.

In addition, several studies have shown that the expression of C18orf25 is associated with the development of cancer-induced metastasis. For example, one study published in the journal Cancer Research found that the expression of C18orf25 was significantly increased in human colorectal cancer samples compared to the control samples.

Conclusion

C18orf25 is a gene that has been identified in various cancer types and has been shown to play a role in the regulation of cell cycle progression, apoptosis, and inflammation. Its expression has been shown to be significantly increased in various types of cancer, including breast , ovarian, and colorectal cancers, and it has also been associated with the development of cancer-induced metastasis.

Given its unique structure and bioactivity, C18orf25 is a promising candidate as a drug target and biomarker for various types of cancer. Further research is needed to fully understand its role in cancer development and to develop effective treatments based on its potential.

Protein Name: Chromosome 18 Open Reading Frame 25

Functions: AMPK substrate important for exercise capacity and skeletal muscle function. Required for normal contraction-induced signaling

The "C18orf25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C18orf25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets